Dr. Elizabeth Conner Discusses DCP as a Biomarker for Hepatocellular Carcinoma at ASCO GI 2024
By Elizabeth Conner, MD - Last Updated: March 19, 2025At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Dr. Elizabeth Conner from the University of California, San Diego, offered insight on how des-gamma-carboxy prothrombin can be utilized as a biomarker for treatment response in patients with HCC receiving first-line treatment of atezolizumab/bevacizumab.
Catch up on more ASCO GI 2024 coverage here.
Advertisement
Post Tags:ASCO GI 2024: Focus on Liver Cancer
Advertisement
Related Posts
In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1.
Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%.
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Dr. Ethan Ludmir discusses the phase II EXTEND trial on MDT with systemic therapy for pancreatic ductal adenocarcinoma.
Dr. Lieu discusses the CIRCULATE-NORTH AMERICA trial on ctDNA status as a biomarker for risk stratification in colon cancer.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.